Match Document Document Title
7125890 Ether substituted imidazopyridines  
Imidazopyridine compounds that contain an ether or thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the...
7122557 Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors  
The present application describes sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds and derivatives thereof of Formula I:
7115596 Thiazole compounds as integrin receptor antagonists derivatives  
The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula...
7115627 Glycinamides as factor Xa inhibitors  
The present application describes glycinamidic compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
7109192 Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions  
The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein R 1 to R 4 are defined as in claim 1 , the tautomers, the stereoisomers,...
7101884 Tyrosine kinase inhibitors  
The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to...
7098220 Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same  
Compounds of formula (I): wherein: R 1 represents hydrogen, halogen, alkyl, polyhaloalkyl, cyano, nitro, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or...
7098221 Amide substituted imidazopyridines  
Imidazopyridine compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of...
7087603 Pyrazole compounds useful as protein kinase inhibitors  
This invention describes novel pyrazole compounds of formula IV: wherein Z 1 or Z 2 is nitrogen, Q is —S—, —O—, —N(R 4 )—, —C(R 6′ ) 2 —, 1,2-cyclopropanediyl,...
7081464 Topical compositions of cyclic amides as immunotherapeutic agents  
Novel amides and imides are inhibitors of tumor necrosis factorα and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory...
7053093 Bicyclic and tricyclic hetroaromatic compounds  
Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X 1 , Y and Z are as defined herein. These compounds bind with high selectivity...
7053103 Ring fused pyrazole derivatives as CRF antagonists  
This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl,...
7045529 Imidazopyrimidinyl and imidazopyri dinyl derivatives  
Provided herein are compounds of the formula (I): as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful...
7041675 Heterocyclic compounds and their use as PARP inhibitors  
The invention relates to compounds of the formula I and the tautomeric forms, possible enantiomeric and diasteromeric forms thereof, and prodrugs thereof, and use thereof as PARP inhibitors.
7041667 CCR5 modulators  
Compounds of Formula 1 [R egion α]—[R egion β]—[R egion γ]—[R egion δ] (1)
7037923 Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines  
The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them...
7034038 Enantiomer (-) of tenatoprazole and the therapeutic use thereof  
The invention relates to enantiomer (−) of tentoprazole. The inventive enantiomer (−) of tenatoprazole, or...
7022712 Solubilization of weak bases  
A pharmaceutical composition for administration to mammals comprising: a weak base compound having a compound pKa below about 7; an acidic buffer with a buffer pKa below 7; and optional...
7012080 Imidazopyridine compounds as 5-HT4 receptor agonists  
This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 represents a hydrogen atom or a halogen atom; R 2 represents a methyl group...
6984646 Imidazopyridinones as p38 map kinase inhibitors  
The invention relates to imidazopyridinones of the formula wherein the groups R 1 , R 2 , R 3 , and R 4 are as defined in claim 1, to the process for their preparation, to pharmaceutical...
6977262 Dihydropyrazolopyridine compounds and pharmaceutical use thereof  
The present invention provides dihydropyrazolopyridine compounds represented by the formula (I): wherein each symbol is as defined in the specification, optically active forms thereof, and...
6974808 CRF receptor antagonists and methods relating thereto  
CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded...
6969712 Benzimidazole derivatives  
This invention relates to the compounds represented by a general formula [I]: [in which A 1 and A 2 represent optionally fluorine-substituted methine or the like; B represents halogen,...
6969722 Amide substituted imidazopyridines  
Imidazopyridine compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of...
6964957 Fused pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity  
Pyrazole compounds represented by the formula: are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in...
6962926 Antagonist of MCP-1 function, and compositions and methods of use thereof  
Compounds of formula A and formula B: and their pharmaceutically acceptable salts, compositions comprising them, methods for their use, and their use in the preparation of medicaments. The...
6960591 Propane-1,3-dione derivative  
Provided is a pharmaceutical composition containing a propane-1,3-dione derivative as the active ingredient, particularly a GnRH receptor antagonist. Also, provided is a propane-1,3-dione...
6960595 5-6 to 5-7 Heterobicycles as factor Xa inhibitors  
The present application describes 5-6 or 5-7 heterobicyclics of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P is a 5-membered heteroaromatic and ring M is a 6 or...
6953793 Substituted pyrazoles  
Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.
6951863 Pyridoarylphenly oxazolidinone antibacterials, and related compositions and methods  
Pyridoarylphenyl oxazolidinone compounds of the formula: in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.
6951867 N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators  
This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt, amide or ester thereof, wherein R 1 represents a hydrogen atom or a halogen atom; R 2 represents...
6949564 NPY-5 antagonists  
The present invention provides NPY-5 receptor antagonists having a Formula (IA) Methods and pharmaceutical compositions useful for treating diseases, conditions and/or disorders modulated by...
6946473 Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors  
Compounds of the formula which are useful in disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's...
6943175 2-NH-heteroarylimidazoles with antibacterial activity  
Compounds of formula (I): are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.
6933305 Amide compounds and use thereof  
The present invention relates to an amide compound of the formula wherein R 1 is a hydrogen and the like, R 2 is a hydrogen and the like, X is SO 2 and the like, Y is the formula (III) and...
6921759 Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors  
Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV...
6919329 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives  
The present invention provides antibacterial agents having the formulae I, II, and III described herein.
6919331 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents  
The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides...
6916827 Substituted ring-fused imidazole derivative: GABAA receptors ligands  
Substituted ring-fused imidazole derivatives that bind to GABA A receptors are provided. Such compounds may be used to modulate ligand binding to GABA A receptors in vivo or in vitro, and are...
6908926 Substituted imidazoles, their preparation and use  
Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and/or prevention of diseases and disorders...
6903113 Urea substituted imidazopyridines  
Imidazopyridine compounds that contain urea or thiourea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the...
6903112 Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands  
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
6897223 Pyridine fused bicyclic metalloproteinase inhibitors  
The present invention relates to fused bicyclic metalloproteinase inhibitors of the formula wherein A, B, X, Y, and R 1 are as defined in the specification, and to pharmaceutical compositions...
6890934 Sulfonamide compounds and uses thereof as medicines  
The present invention relates to a sulfonamide compound of the formula (I): wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing...
6887885 Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands  
A compound of formula I, or a pharmaceutically acceptable salt thereof: wherein X 1 represents hydrogen, halogen, C 1-6 alkyl, trifluoromethyl or C 1-6 alkoxy; X 2 represents...
6878719 Sulfonamido substituted imidazopyridines  
Imidazopyridine compounds that contain sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the...
6875765 Arylsulfonamide ethers, and methods of use thereof  
The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family are...
6872730 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists  
The present invention relates to novel substituted benzofurans and benzothiophenes compounds that are antagonists of alpha V (αv) integrins, for example α v β 3 and α v β 5 integrins, their...
6867208 Vitronectin receptor antagonists, their preparation and their use  
The present invention relates to compounds of the formula I A—B—D—E—F—G (I)
6867202 Treatment of insulin resistance  
This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in...